3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Chemical Dependence in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferrari, MD; Saxena, PR; van Royen, EA; Verhoeff, NP; Visser, WH | 1 |
| Klimke, A; Larisch, R | 1 |
2 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Chemical Dependence
| Article | Year |
|---|---|
Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier?
Topics: Benzamides; Blood-Brain Barrier; Brain; Contrast Media; Dopamine D2 Receptor Antagonists; Ergotamine; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Migraine Disorders; Pyrrolidines; Receptors, Dopamine D2; Substance Withdrawal Syndrome; Substance-Related Disorders; Tomography, Emission-Computed, Single-Photon | 1993 |
[Clinical impact of cerebral dopamine-D2 receptor scintigraphy].
Topics: Benzamides; Brain; Carbon Radioisotopes; Fluorine Radioisotopes; Humans; Iodine Radioisotopes; Mental Disorders; Parkinson Disease; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Substance-Related Disorders; Tissue Distribution; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1998 |